darunavir has been researched along with rifampin in 6 studies
| Studies (darunavir) | Trials (darunavir) | Recent Studies (post-2010) (darunavir) | Studies (rifampin) | Trials (rifampin) | Recent Studies (post-2010) (rifampin) |
|---|---|---|---|---|---|
| 1,148 | 224 | 780 | 20,468 | 1,499 | 6,552 |
| Protein | Taxonomy | darunavir (IC50) | rifampin (IC50) |
|---|---|---|---|
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 2.949 | |
| Caspase-1 | Homo sapiens (human) | 8.319 | |
| Alpha-synuclein | Homo sapiens (human) | 7.1 | |
| Enoyl-[acyl-carrier-protein] reductase [NADH] | Mycobacterium tuberculosis H37Rv | 0.03 | |
| DNA-directed RNA polymerase subunit beta | Mycobacterium tuberculosis H37Rv | 0.01 | |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 1.5 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 1.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Aïssi, E; Ettahar, N; Huleux, T; Massongo, M; Melliez, H; Pasquet, A; Yazdanpanah, Y | 1 |
| Annaert, P; Augustijns, P; Baes, M; Gonzalez, FJ; Holmstock, N | 1 |
| Back, D; Boffito, M; Dickinson, L; Khoo, S; Siccardi, M; Winston, A | 1 |
| Khoo, S; Owen, A; Roberts, O; Siccardi, M | 1 |
| Ebrahim, I; Maartens, G; McIlleron, H; Orrell, C; Smythe, W; Wiesner, L | 1 |
1 review(s) available for darunavir and rifampin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for darunavir and rifampin
| Article | Year |
|---|---|
Pharmacokinetic profile and safety of adjusted doses of darunavir/ritonavir with rifampicin in people living with HIV.
Topics: Anti-HIV Agents; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Rifampin; Ritonavir | 2020 |
4 other study(ies) available for darunavir and rifampin
| Article | Year |
|---|---|
[Immune reconstitution syndrome related to a Mycobacterium avium complex infection, revealed by a mono-adenitis].
Topics: Abscess; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Axilla; Clarithromycin; Darunavir; Dideoxynucleosides; Enfuvirtide; Ethambutol; HIV Envelope Protein gp41; HIV-1; Humans; Immune Reconstitution Inflammatory Syndrome; Isoniazid; Lamivudine; Lymph Node Excision; Lymphadenitis; Male; Mycobacterium avium-intracellulare Infection; Peptide Fragments; Pyrazinamide; Rifampin; Ritonavir; Streptomycin; Sulfonamides | 2011 |
PXR/CYP3A4-humanized mice for studying drug-drug interactions involving intestinal P-glycoprotein.
Topics: Acridines; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Darunavir; Drug Interactions; Humans; Intestinal Absorption; Intestinal Mucosa; Intestines; Male; Mice; Mice, Transgenic; Models, Animal; Pregnane X Receptor; Receptors, Steroid; Rifampin; Sulfonamides; Tetrahydroisoquinolines; Xenobiotics | 2013 |
Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach.
Topics: Adult; Area Under Curve; Computer Simulation; Darunavir; Drug Administration Schedule; Drug Interactions; Female; Humans; Male; Middle Aged; Models, Theoretical; Rifampin; Ritonavir; Young Adult | 2016 |
Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat
Topics: Antirheumatic Agents; Antitubercular Agents; Cells, Cultured; Cobicistat; Darunavir; Drug Interactions; Drug Therapy, Combination; Hepatocytes; HIV Infections; HIV-1; Humans; Metabolic Clearance Rate; Mycobacterium tuberculosis; Rifampin; Ritonavir; Tuberculosis, Pulmonary | 2017 |